Ligand Pharmaceuticals Inc (NASDAQ: LGND) has reported E.P.S. of $-1.64 for its fourth fiscal quarter (ending December 31) versus $1.04 for the same period a year ago — a decline of -258%. For the latest four quarters through December 31, E.P.S. were $-0.22 compared to $3.11 a year ago — a decline of -107%.
Recent Price Action
On 2/27/25, Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock rose modestly by 0.6%, closing at $115.67. Moreover, unusually high trading volume at 151% of normal accompanied the advance. The stock has declined -5.2% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Ligand Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Ligand Pharmaceuticals has a poor Appreciation Score of 20 but a good Power Rating of 73, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment